Targeting antioxidant and antithrombotic biotherapeutics to endothelium

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 3, 2010, Pages 332-342

  Carnemolla, Ronald ^a   Shuvaev, Vladimir V ^a   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antioxidants; Drug delivery; Endothelium; Nanocarriers; Targeted therapeutics; Thromboprophylaxis

Indexed keywords

ANTIOXIDANT; CATALASE; CD31 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE ANTIBODY; FIBRINOLYTIC AGENT; GLYCOPROTEIN; GLYCOPROTEIN GP85; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LIPOSOME; NANOCARRIER; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 ANTIBODY; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 ANTIBODY CATALASE CONJUGATE; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 ANTIBODY SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY PROUROKINASE FUSION PROTEIN; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 ANTIBODY SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY UROKINASE PLASMINOGEN ACTIVATOR THROMBIN; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 ANTIBODY SUPEROXIDE DISMUTASE CONJUGATE; POLYMER; PROTEIN ANTIBODY; PROUROKINASE; REACTIVE OXYGEN METABOLITE; SELECTIN; SUPEROXIDE DISMUTASE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY CONJUGATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

BRAIN EMBOLISM; CELL INFILTRATION; CELL MEMBRANE; CONJUGATION; DRUG ACCUMULATION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENCAPSULATION; ENDOTHELIUM; ENDOTHELIUM CELL; INTERNALIZATION; LEUKOCYTE; LUNG BLOOD VESSEL; LUNG EMBOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS;

EID: 77953274168     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1253455     Document Type: Review

References (116)

1. Muzykantov V R. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin Drug Deliv 2005 2 (5) 909-926
2. Hajitou A, Trepel M, Lilley C E. et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006 125 (2) 385-398
3. Durr E, Yu J, Krasinska K M. et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 2004 22 (8) 985-992
4. Oh P, Li Y, Yu J et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004 429 (6992) 629-635
5. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998 102 (2) 430-437
6. Ghitescu L, Jacobson B S., Crine P. A novel, 85 kDa endothelial antigen differentiates plasma membrane macrodomains in lung alveolar capillaries. Endothelium 1999 6 (3) 241-250
7. Murciano J C., Harshaw D W., Ghitescu L, Danilov S M., Muzykantov V R. Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries. Am J Respir Crit Care Med 2001 164 (7) 1295-1302
8. Oh P, Borgström P, Witkiewicz H et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 2007 25 (3) 327-337
9. Muzykantov V R., Puchnina E A., Atochina E N. et al. Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme. J Nucl Med 1991 32 (3) 453-460
10. Danilov S, Atochina E, Hiemisch H et al. Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: antibody targeting to the lung induces ACE antigenic modulation. Int Immunol 1994 6 (8) 1153-1160
11. Danilov S M., Gavrilyuk V D., Franke F E. et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 2001 280 (6) L1335-L1347
12. Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1-7)- stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001 37 (1) 72-76 (Pubitemid 32064242)
13. Muzykantov V R., Atochina E N., Kuo A et al. Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. Am J Physiol 1996 270 (5 Pt 1) L704-L713
14. Danilov S M., Martynov A V., Klibanov A L. et al. Radioimmunoimaging of lung vessels: an approach using indium-111-labeled monoclonal antibody to angiotensin-converting enzyme. J Nucl Med 1989 30 (10) 1686-1692
15. Balyasnikova I V., Metzger R, Visintine D J. et al. Selective rat lung endothelial targeting with a new set of monoclonal antibodies to angiotensin I-converting enzyme. Pulm Pharmacol Ther 2005 18 (4) 251-267
16. Balyasnikova I V., Sun Z L., Metzger R et al. Monoclonal antibodies to native mouse angiotensin-converting enzyme (CD143): ACE expression quantification, lung endothelial cell targeting and gene delivery. Tissue Antigens 2006 67 (1) 10-29
17. Muzykantov V R., Danilov S M. Targeting of radiolabeled monoclonal antibody against ACE to the pulmonary endothelium In: Torchilin V Targeted Delivery of Imaging Agents. Roca Baton, FL CRC Press 1995 465-485
18. Muzykantov V R., Atochina E N., Ischiropoulos H, Danilov S M., Fisher A B. Immunotargeting of antioxidant enzyme to the pulmonary endothelium. Proc Natl Acad Sci U S A 1996 93 (11) 5213-5218
19. Atochina E N., Balyasnikova I V., Danilov S M., Granger D N., Fisher A B., Muzykantov V R. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am J Physiol 1998 275 (4 Pt 1) L806-L817
20. Nowak K, Weih S, Metzger R et al. Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. Am J Physiol Lung Cell Mol Physiol 2007 293 (1) L162-L169
21. Watanabe K, Lam G, Keresztes R S., Jaffe E A. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells. J Cell Physiol 1992 150 (2) 433-439
22. Atochina E N., Hiemisch H H., Muzykantov V R., Danilov S M. Systemic administration of platelet-activating factor in rat reduces specific pulmonary uptake of circulating monoclonal antibody to angiotensin-converting enzyme. Lung 1992 170 (6) 349-358
23. Scherpereel A, Wiewrodt R, Christofidou-Solomidou M et al. Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting. FASEB J 2001 15 (2) 416-426
24. Danielyan K, Ding B S., Gottstein C, Cines D B., Muzykantov V R. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther 2007 321 (3) 947-952
25. Garnacho C, Dhami R, Simone E et al. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther 2008 325 (2) 400-408
26. Muro S, Dziubla T, Qiu W et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther 2006 317 (3) 1161-1169
27. Muro S, Muzykantov V R. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 2005 11 (18) 2383-2401
28. Nakada M T., Amin K, Christofidou-Solomidou M et al. Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment. J Immunol 2000 164 (1) 452-462
29. Murohara T, Delyani J A., Albelda S M., Lefer A M. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. J Immunol 1996 156 (9) 3550-3557
30. Kumasaka T, Quinlan W M., Doyle N A. et al. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest 1996 97 (10) 2362-2369
31. Muro S, Wiewrodt R, Thomas A et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003 116 (Pt 8) 1599-1609
32. Muzykantov V R., Christofidou-Solomidou M, Balyasnikova I et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc Natl Acad Sci U S A 1999 96 (5) 2379-2384
33. Albelda S M. Endothelial and epithelial cell adhesion molecules. Am J Respir Cell Mol Biol 1991 4 (3) 195-203
34. Wiewrodt R, Thomas A P., Cipelletti L et al. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 2002 99 (3) 912-922
35. Christofidou-Solomidou M, Pietra G G., Solomides C C. et al. Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs. Am J Physiol Lung Cell Mol Physiol 2000 278 (4) L794-L805
36. Scherpereel A, Rome J J., Wiewrodt R et al. Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J Pharmacol Exp Ther 2002 300 (3) 777-786
37. Li S, Tan Y, Viroonchatapan E, Pitt B R., Huang L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am J Physiol Lung Cell Mol Physiol 2000 278 (3) L504-L511
38. Muro S, Cui X, Gajewski C, Murciano J C., Muzykantov V R., Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 2003 285 (5) C1339-C1347
39. Almenar-Queralt A, Duperray A, Miles L A., Felez J, Altieri D C. Apical topography and modulation of ICAM-1 expression on activated endothelium. Am J Pathol 1995 147 (5) 1278-1288
40. Panés J, Perry M A., Anderson D C. et al. Regional differences in constitutive and induced ICAM-1 expression in vivo. Am J Physiol 1995 269 (6 Pt 2) H1955-H1964
41. Murciano J C., Muro S, Koniaris L et al. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003 101 (10) 3977-3984
42. Beck-Schimmer B, Schimmer R C., Warner R L. et al. Expression of lung vascular and airway ICAM-1 after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 1997 17 (3) 344-352
43. Vaporciyan A A., Mulligan M S., Warren J S., Barton P A., Miyasaka M, Ward P A. Up-regulation of lung vascular ICAM-1 in rats is complement dependent. J Immunol 1995 155 (3) 1442-1449
44. Sasso D E., Gionfriddo M A., Thrall R S., Syrbu S I., Smilowitz H M., Weiner R E. Biodistribution of indium-111-labeled antibody directed against intercellular adhesion molecule-1. J Nucl Med 1996 37 (4) 656-661
45. Villanueva F S., Jankowski R J., Klibanov S et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998 98 (1) 1-5
46. Bloemen P G., Henricks P A., van Bloois L et al. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett 1995 357 (2) 140-144
47. Kishimoto T K., Rothlein R. Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv Pharmacol 1994 25 117-169
48. Springer T A. Adhesion receptors of the immune system. Nature 1990 346 (6283) 425-434
49. Spragg D D., Alford D R., Greferath R et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A 1997 94 (16) 8795-8800
50. Kiely J M., Cybulsky M I., Luscinskas F W., Gimbrone M A. Jr. Immunoselective targeting of an anti-thrombin agent to the surface of cytokine-activated vascular endothelial cells. Arterioscler Thromb Vasc Biol 1995 15 (8) 1211-1218
51. Kuijpers T W., Raleigh M, Kavanagh T et al. Cytokine-activated endothelial cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape. A tubulin-driven process. J Immunol 1994 152 (10) 5060-5069
52. Straley K S., Green S A. Rapid transport of internalized P-selectin to late endosomes and the TGN: roles in regulating cell surface expression and recycling to secretory granules. J Cell Biol 2000 151 (1) 107-116
53. von Asmuth E J., Smeets E F., Ginsel L A., Onderwater J J., Leeuwenberg J F., Buurman W A. Evidence for endocytosis of E-selectin in human endothelial cells. Eur J Immunol 1992 22 (10) 2519-2526
54. Kessner S, Krause A, Rothe U, Bendas G. Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells. Biochim Biophys Acta 2001 1514 (2) 177-190
55. Kok R J., Everts M, Asgeirsdóttir S A., Meijer D K., Molema G. Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: comparison with free dexamethasone. Pharm Res 2002 19 (11) 1730-1735
56. Harari O A., Wickham T J., Stocker C J. et al. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther 1999 6 (5) 801-807
57. Lindner J R., Song J, Christiansen J, Klibanov A L., Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 2001 104 (17) 2107-2112
58. Kelly K A., Allport J R., Tsourkas A, Shinde-Patil V R., Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005 96 (3) 327-336
59. Keelan E T., Harrison A A., Chapman P T., Binns R M., Peters A M., Haskard D O. Imaging vascular endothelial activation: an approach using radiolabeled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin. J Nucl Med 1994 35 (2) 276-281
60. Lindner J R., Klibanov A L., Ley K. Targeting inflammation In: Muzykantov VR, Torchilin VP Biomedical Aspects of Drug Targeting. Boston, MA Kluwer Academic Publications 2003 149-172
61. Bonaventura J, Gow A. NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc Natl Acad Sci U S A 2004 101 (47) 16403-16404
62. Christofidou-Solomidou M, Muzykantov V R. Antioxidant strategies in respiratory medicine. Treat Respir Med 2006 5 (1) 47-78
63. Cai H, Griendling K K., Harrison D G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003 24 (9) 471-478
64. McCord J M. Superoxide dismutase in aging and disease: an overview. Methods Enzymol 2002 349 331-341
65. Kinnula V L., Crapo J D. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003 167 (12) 1600-1619
66. Beckman J S., Minor R L. Jr, White C W., Repine J E., Rosen G M., Freeman B A. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J Biol Chem 1988 263 (14) 6884-6892
67. Giri S N., Misra H P. Fate of superoxide dismutase in mice following oral route of administration. Med Biol 1984 62 (5) 285-289
68. Corvo M L., Boerman O C., Oyen W J. et al. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. Biochim Biophys Acta 1999 1419 (2) 325-334
69. Fujita T, Nishikawa M, Tamaki C, Takakura Y, Hashida M, Sezaki H. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono-and polysaccharide derivatives. J Pharmacol Exp Ther 1992 263 (3) 971-978
70. Freeman B A., Young S L., Crapo J D. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem 1983 258 (20) 12534-12542
71. Day B J., Shawen S, Liochev S I., Crapo J D. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J Pharmacol Exp Ther 1995 275 (3) 1227-1232
72. Duann P, Datta P K., Pan C, Blumberg J B., Sharma M, Lianos E A. Superoxide dismutase mimetic preserves the glomerular capillary permeability barrier to protein. J Pharmacol Exp Ther 2006 316 (3) 1249-1254
73. Tamura Y, Chi L G., Driscoll E M. Jr, et al. Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemia/reperfusion injury in canine heart. Circ Res 1988 63 (5) 944-959
74. Igarashi R, Hoshino J, Ochiai A, Morizawa Y, Mizushima Y. Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J Pharmacol Exp Ther 1994 271 (3) 1672-1677
75. Koo D D., Welsh K I., West N E. et al. Endothelial cell protection against ischemia/reperfusion injury by lecithinized superoxide dismutase. Kidney Int 2001 60 (2) 786-796
76. Ishihara T, Tanaka K, Tasaka Y et al. Therapeutic effect of lecithinized superoxide dismutase against colitis. J Pharmacol Exp Ther 2009 328 (1) 152-164
77. Lee S, Murthy N. Targeted delivery of catalase and superoxide dismutase to macrophages using folate. Biochem Biophys Res Commun 2007 360 (1) 275-279
78. Gow A, Ischiropoulos H. Super-SOD: superoxide dismutase chimera fights off inflammation. Am J Physiol Lung Cell Mol Physiol 2003 284 (6) L915-L916
79. Bonder C S., Knight D, Hernandez-Saavedra D, McCord J M., Kubes P. Chimeric SOD2/3 inhibits at the endothelial-neutrophil interface to limit vascular dysfunction in ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2004 287 (3) G676-G684
80. Gao B, Flores S C., Leff J A., Bose S K., McCord J M. Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3. Am J Physiol Lung Cell Mol Physiol 2003 284 (6) L917-L925
81. Grey M, Yainoy S, Prachayasittikul V, Bülow L. A superoxide dismutase-human hemoglobin fusion protein showing enhanced antioxidative properties. FEBS J 2009 276 (21) 6195-6203
82. Lu M, Gong X, Lu Y, Guo J, Wang C, Pan Y. Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. Inhibition cell proliferation through the Akt/p27kip1 pathway. J Biol Chem 2006 281 (19) 13620-13627
83. Jiang J, Kurnikov I, Belikova N A. et al. Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther 2007 320 (3) 1050-1060
84. Nishikawa M, Hashida M, Takakura Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev 2009 61 (4) 319-326
85. Muzykantov V R., Christofidou-Solomidou M, Balyasnikova I et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc Natl Acad Sci U S A 1999 96 (5) 2379-2384
86. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol 2003 285 (2) L283-L292
87. Shuvaev V V., Dziubla T, Wiewrodt R, Muzykantov V R. Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress. Methods Mol Biol 2004 283 3-19
88. Shuvaev V V., Christofidou-Solomidou M, Bhora F et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther 2009 331 (2) 404-411
89. Kozower B D., Christofidou-Solomidou M, Sweitzer T D. et al. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol 2003 21 (4) 392-398
90. Shuvaev V V., Tliba S, Nakada M, Albelda S M., Muzykantov V R. Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J Pharmacol Exp Ther 2007 323 (2) 450-457
91. Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov V R., Koval M. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol 2006 290 (5) L809-L817
92. Muro S, Gajewski C, Koval M, Muzykantov V R. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 2005 105 (2) 650-658
93. Dziubla T D., Karim A, Muzykantov V R. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Release 2005 102 (2) 427-439
94. Simone E A., Dziubla T D., Arguiri E et al. Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm Res 2009 26 (1) 250-260
95. Dziubla T D., Shuvaev V V., Hong N K. et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 2008 29 (2) 215-227
96. Esmon C T. Inflammation and thrombosis. J Thromb Haemost 2003 1 (7) 1343-1348
97. Bode C, Meinhardt G, Runge M S. et al. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991 84 805-813
98. Runge M S., Quertermous T, Zavodny P J. et al. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci U S A 1991 88 (22) 10337-10341
99. Waugh J M., Kattash M, Li J et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci U S A 1999 96 (3) 1065-1070
100. Topol E J., Byzova T V., Plow E F. Platelet GPIIb-IIIa blockers. Lancet 1999 353 (9148) 227-231
101. Muzykantov V R., Barnathan E S., Atochina E N., Kuo A, Danilov S M., Fisher A B. Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. J Pharmacol Exp Ther 1996 279 (2) 1026-1034
102. Murciano J C., Harshaw D W., Ghitescu L, Danilov S M., Muzykantov V R. Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries. Am J Respir Crit Care Med 2001 164 (7) 1295-1302
103. Ding B S., Zhou Y J., Chen X Y. et al. Lung endothelium targeting for pulmonary embolism thrombolysis. Circulation 2003 108 (23) 2892-2898
104. Muro S, Cui X, Gajewski C, Murciano J C., Muzykantov V R., Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 2003 285 (5) C1339-C1347
105. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003 31 (4, suppl) S213-S220
106. Levi M, Schultz M. The inflammation-coagulation axis as an important intermediate pathway in acute lung injury. Crit Care 2008 12 (2) 144
107. Wu S Q., Aird W C. Thrombin, TNF-alpha, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2005 289 H873-H885
108. Ding B S., Gottstein C, Grunow A et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 2005 106 (13) 4191-4198
109. Stump D C., Lijnen H R., Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986 261 (36) 17120-17126 (Pubitemid 17210366)
110. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002 3 (12) 932-943
111. Liu J N., Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 1992 31 (27) 6311-6317
112. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986 261 (8) 3486-3489
113. Yang W P., Goldstein J, Procyk R, Matsueda G R., Shaw S Y. Design and evaluation of a thrombin-activable plasminogen activator. Biochemistry 1994 33 606-612
114. Ding B S., Hong N, Murciano J C. et al. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 2008 111 (4) 1999-2006
115. Ding B S., Hong N K., Christofidou-Solomidou M et al. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med 2009 180 (3) 247-256
116. Wang Y X., Wu C, Vincelette J et al. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin. Thromb Haemost 2006 96 (3) 317-324